Key Highlights

  • Quarterly Revenue hit USD 275.4 million, up from USD 216.8 million a year earlier, a gain of roughly 27% (calculated from the two reported figures).
  • Net income slipped to USD 15.3 million from USD 24.3 million, but nine-month results moved to USD 14.1 million of income from a USD 150.0 million loss.
  • Clinical cases climbed to 61,500 in the quarter from 50,800, and to 173,500 across nine months from 146,700, per the quarterly report.
  • Cash, restricted cash and marketable securities totaled USD 769.2 million at September 30, 2026, against USD 400.0 million of term Loan principal.

Sales Accelerate While Quarterly Profit Trails

Caris Life Sciences (NASDAQ:CAI) submitted its Quarterly Report on November 4, 2026 for the period ending September 30. Revenue reached USD 275.4 million from USD 216.8 million, while Net Income declined to USD 15.3 million from USD 24.3 million. Nine-month revenue came to USD 755.2 million versus USD 519.1 million, roughly 45% higher (calculated). Over nine months the company moved into a USD 14.1 million net income from a USD 150.0 million net loss. The extract does not explain why quarterly profit fell while sales rose, so no drivers are stated here, and the material holds no guidance or consensus comparison.

Test Volume and New Products Underpin the Top Line

Caris describes itself as a TechBio company that applies molecular data and AI to cancer care, having run tests on more than 1,200,000 cases as of September 30, 2026. Clinical cases grew roughly 21% (calculated) during the quarter to 61,500. In the second quarter it introduced Caris Detect, a multi-cancer early detection blood test, along with Caris ChromoSeq for blood cancers and Caris MI Clarity. The filing lists biopharma collaborators such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech. Revenue comes from molecular profiling services and from pharma Research and Development services, and management expects higher testing volumes and a broader menu to support growth through 2026.

Reimbursement Exposure, Capacity Needs and Cash

The report flags payer coverage as a principal risk for Caris Life Sciences (NASDAQ:CAI), since average selling prices and margins depend on insurer reimbursement. Expanding laboratory capacity, billing and quality systems for new tests is another hurdle, and commercial success for its early detection tests will require more validation studies. Nine-month Operating Cash Flow was USD 39.1 million compared with USD 38.4 million, nearly flat despite far higher revenue. Liquidity of USD 769.2 million stands against a term loan with USD 400.0 million of principal outstanding.

Where Things Stand

Sales growth was strong, but quarterly profit did not follow. Caris Life Sciences (NASDAQ:CAI) grew revenue about 27% and case volume about 21% (both calculated), yet net income fell to USD 15.3 million from USD 24.3 million, and the extract does not explain the gap. The nine-month swing into profit and USD 769.2 million of liquidity are the stronger signals. Watch adoption of Caris Detect and Caris ChromoSeq, payer coverage decisions and how nine-month operating cash flow of USD 39.1 million develops as volumes expand. Revenue growth paired with rising case counts is the clearest operating signal in the extract. Investors should read these figures next to the full quarterly report.